Clinical Trial Update: An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the efficacy and safety of Mongersen (GED-0301) in subjects with active ulcerative colitis has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colitis
• Ulcerative Colitis

Drugs mentioned

• Mongersen (GED-0301)

Snippet

Sponsor: Celgene | Conditions: Colitis, Ulcerative | Phase 2 | Status: COMPLETED | Results posted: 2018-09-12